The Growing Role of Nirsevimab for RSV Prevention

The recent observational study by Irwin N et al. highlights the significant impact of nirsevimab for RSV prevention in the Australian Capital Territory. This research is particularly relevant for Indian clinicians because Respiratory Syncytial Virus (RSV) remains a leading cause of paediatric hospitalisations nationwide. Furthermore, the Central Drugs Standard Control Organisation (CDSCO) recently approved nirsevimab in India. Therefore, understanding its real-world efficacy in reducing severe lower respiratory tract infections (LRTI) is crucial for improving neonatal outcomes. Notably, the study focused on infants aged to assess how a targeted program changes epidemiological trends.

Assessing the Efficacy of Nirsevimab for RSV Prevention

The study specifically monitored infants eligible for the long-acting monoclonal antibody. Consequently, the researchers observed a marked decline in both infection rates and hospital admissions. Moreover, this protective effect persisted throughout the peak RSV season. Notably, even with limited eligibility criteria, the program successfully alleviated the burden on tertiary care facilities. Thus, the findings support the broader implementation of such preventative measures in high-burden regions like India. Additionally, data suggests that passive immunisation can reduce the severity of symptoms in those who do contract the virus.

Experts in India emphasize that while hygiene is essential, it often fails to stop RSV transmission. Therefore, the arrival of nirsevimab represents a major technological advancement. Specifically, a single dose provides passive immunity for approximately five months. This long-lasting protection is vital since most RSV-related deaths in India occur within the first year of life. Furthermore, clinical trials have shown a safety profile comparable to placebo, making it a reliable choice for the most vulnerable neonates.

Clinical Relevance for Indian Paediatric Practice

India currently accounts for a substantial portion of global RSV cases, with approximately 1 lakh annual hospitalisations. However, the introduction of nirsevimab offers a promising solution to this public health challenge. Doctors should consider this therapy for neonates entering the monsoon or early winter peaks, which are high-risk periods in the subcontinent. Furthermore, paediatricians can safely co-administer it with routine vaccines. Consequently, this simplifies the immunisation schedule for parents and ensures timely protection. By implementing nirsevimab for RSV prevention, healthcare providers can significantly lower the incidence of bronchiolitis and pneumonia among infants.

Frequently Asked Questions

How does nirsevimab differ from a traditional vaccine?

Nirsevimab is a long-acting monoclonal antibody that provides passive immunity by delivering ready-made antibodies directly to the infant. In contrast, traditional vaccines teach the body to produce its own antibodies over time.

Is nirsevimab approved for use in India?

Yes, the CDSCO approved nirsevimab in August 2024. It is recommended for all infants entering their first RSV season to prevent severe lower respiratory tract infections.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Irwin N et al. The Impact of Limited-Eligibility Nirsevimab on Paediatric Respiratory Syncytial Virus (RSV) Infection and Hospitalisations in the Australian Capital Territory: An Observational Cohort Study. J Paediatr Child Health. 2026 May 06. doi: 10.1111/jpc.70402. PMID: 42089248.

KinderCure Clinic. RSV Vaccine Now Available in India: What Parents Need to Know About Nirsevimab. 2026.

National Institutes of Health (PMC). Disease burden due to respiratory syncytial virus infection among under-5 children of India for 2020: a multiplicative model using meta-estimates. 2025.